Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Nonunion of Limb Fracture With Human Amniotic Epithelial Cells(hAECs)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03031509
Recruitment Status : Not yet recruiting
First Posted : January 25, 2017
Last Update Posted : June 5, 2017
Sponsor:
Collaborator:
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Information provided by (Responsible Party):
Shanghai East Hospital

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of human amniotic epithelial cells transplant in nonunion of limb fracture patients.

Condition or disease Intervention/treatment Phase
Nonunion Fracture Biological: Human Amniotic Epithelial Cells Procedure: debridement Phase 1 Phase 2

Detailed Description:

In this study, patients of nonunion after limb fracture will be treated with human amniotic epithelial cells. Clinical and radiological assessment is performed.

hAECs developing from the epiblast as early as 8 days after fertilization, recent data reported indicate that hAECs possess proper osteogenic differentiation potential and a localized modulatory influence on the early tissue remodeling process, making these cells a promising stem cell source for bone regeneration after fractures.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Treatment of Nonunion of Limb Fracture With Human Amniotic Epithelial Cells(hAECs)
Estimated Study Start Date : December 2017
Estimated Primary Completion Date : March 2018
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fractures

Arm Intervention/treatment
Experimental: hAECs treatment
Human Amniotic Epithelial Cells of 50 million transplant to nonunion site after debridement surgery
Biological: Human Amniotic Epithelial Cells
Human Amniotic Epithelial Cells transplant after debridement

Procedure: debridement
debridement

Sham Comparator: debridement surgery
debridement surgery
Procedure: debridement
debridement




Primary Outcome Measures :
  1. time for bone union [ Time Frame: 6 months ]
    Bone union was evaluated at 6-month after surgery according to the following definition.Definition of bone union is when simple X-ray findings reveal that bone trabeculae or cortical bone exceeds the fracture site.


Secondary Outcome Measures :
  1. pain in fracture site [ Time Frame: 1 year ]
  2. limb functional score [ Time Frame: 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • diagnosed with nonunion of limbs by x-ray and bone scan;
  • compliance to treatment and long term follow-up;
  • be able and willing to participate in the study;
  • written informed consent before study.

Exclusion Criteria:

  • pregnant or breastfeeding;
  • patients with malignancy, immunocompromised ( HIV AIDS, Diabetes mellitus, active Hepatitis), in a immunosuppressant therapy ( chemotherapy or steroids), OR health status, mental diseases, which will influence the study;
  • patients undergoing any other treatment that are not related to this study;
  • others considered not appropriate selected patients.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03031509


Contacts
Layout table for location contacts
Contact: Xia LI, Dr. 86-21-38804518 ext 14185 daxia868@163.com

Locations
Layout table for location information
China
Shanghai East Hospital
Shanghai, China, 021
Contact: LIN LI    86-021-61569006 ext 9829      
Sponsors and Collaborators
Shanghai East Hospital
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Investigators
Layout table for investigator information
Principal Investigator: XIA LI, Dr. Shanghai East Hospital
Publications:
Layout table for additonal information
Responsible Party: Shanghai East Hospital
ClinicalTrials.gov Identifier: NCT03031509    
Other Study ID Numbers: DFSC-2017(CR)-01
First Posted: January 25, 2017    Key Record Dates
Last Update Posted: June 5, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Shanghai East Hospital:
Nonunion Fracture of limb
Additional relevant MeSH terms:
Layout table for MeSH terms
Fractures, Bone
Fractures, Ununited
Wounds and Injuries